1.69
-0.09(-5.06%)
Currency In USD
| Previous Close | 1.78 |
| Open | 1.77 |
| Day High | 1.8 |
| Day Low | 1.68 |
| 52-Week High | 2.27 |
| 52-Week Low | 0.77 |
| Volume | 2.48M |
| Average Volume | 3.09M |
| Market Cap | 168.62M |
| PE | -4.69 |
| EPS | -0.36 |
| Moving Average 50 Days | 1.8 |
| Moving Average 200 Days | 1.35 |
| Change | -0.09 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.03 as of July 30, 2025 at a share price of $1.69. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $526.48 as of July 30, 2025 at a share price of $1.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
GlobeNewswire Inc.
Jul 15, 2025 11:45 AM GMT
The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomo
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
GlobeNewswire Inc.
Jul 07, 2025 12:45 PM GMT
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
GlobeNewswire Inc.
Jun 24, 2025 12:00 PM GMT
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indica